



20  
24

ANNUAL REPORT



# TABLE OF CONTENTS

Mission.....	3
From the CEO.....	4
Core Pillars.....	6
Leadership.....	7
Global Impact.....	8
Strategic Partners.....	9
Donor Community.....	11
Patient Impact.....	16
Financials.....	18

# OUR MISSION

TO IMPROVE QUALITY OF LIFE BY  
TRANSFORMING THE  
UNDERSTANDING, TREATMENT, AND  
CARE OF THE OCULAR SURFACE

# LETTER FROM THE CEO



It is my privilege to share BostonSight's 2024 Annual Report. This year marked a period of measurable progress, strategic growth, and meaningful impact—all made possible through your support.

In 2024, BostonSight raised more than \$300,000 to advance our vision of a world where no one suffers loss of sight from irregular corneas or ocular surface disease. These funds directly supported our core pillars of Clinical Care, Research and Innovation, Technology, and Education, enabling us to:

- Provide financial assistance to patients who would otherwise be unable to afford sight-saving treatment.
- Conduct and publish industry-leading research, including a 21-year retrospective review of pediatric scleral lenses and a groundbreaking investigation of PROSE® as a drug-delivery device.
- Expand our global reach by growing the BostonSight SCLERAL® network in the U.S., Canada, UK, EU, and Latin America.
- Strengthen our clinical leadership through participation in dozens of educational and professional events across the world, often as invited speakers.
- Invest in technology and manufacturing capacity, including new lens design software evaluations, lab expansion, and lean manufacturing training, allowing us to deliver best-in-class specialty lenses to patients, and deliver them quickly.
- Share our knowledge and experience through FitAcademy™, FitSmart™ events, and the first Global Education Partner Summit which brought together our international partners.

These accomplishments underscore the strength of our model: Integrating clinical expertise, research, engineering, technology, and education to deliver sustainable solutions in corneal care. The true measure of success lies in our impact on patients—individuals who gain not only vision but also quality of life and independence because of your support.

Looking ahead, 2025 will mark the launch of our new five-year strategic plan, which will guide BostonSight toward continued innovation, expanded access to specialty lenses, and strengthened global collaborations. With your ongoing partnership, we are well-positioned to deliver on our mission at greater scale and with greater impact.

On behalf of our board of directors, clinicians, and staff, I would like to extend our sincere gratitude for your commitment to BostonSight. Together, we are advancing the future of ocular health and ensuring that patients worldwide have access to life-changing treatment.

Sincerely,

Sara Yost, MBA  
President & CEO

2024 Funds Raised: \$300,000



# CORE PILLARS

## CLINICAL CARE



We demonstrate how specialty lenses positively impact patient ocular health and quality of life. What we did in 2024:

- Surveyed PROSE patients to document the efficacy of their treatment and impact on their lives
- Broadened sources of fund development through our base and peer-supported events to achieve greater patient financial support
- Implemented quarterly updates to keep donors abreast of clinic developments and mission impact
- Increased awareness of the impact of PROSE and scleral lenses in the treatment of ocular surface disease

## TECHNOLOGY



We drive innovation to improve specialty lens technology. What we did in 2024:

- Embarked on a significant evaluation of existing lens design software and identified areas for upgrade in 2025
- Utilized instrument-based topography systems to improve patient outcomes
- Utilized new technology to manufacture lenses with higher-order aberration (HOA) correction
- Created greater manufacturing flexibility, efficiency, and capacity by adding new lathes to our lab, expanding our physical footprint, and implementing lean manufacturing methods

## RESEARCH AND INNOVATION



We fuel research to influence ocular health benefits of specialty lenses and drive innovation. What we did in 2024:

- Published industry-leading papers, including a 21-Year Retrospective Review of Pediatric Scleral Lenses and Utilizing PROSE as a Drug Delivery Device for Preservative-Free Cyclosporine 0.05% for the Treatment of Dry Eye Disease
- Attended or were invited speakers at 31 events across ophthalmology and optometry (U.S., Italy, Spain, Portugal, Colombia, and Canada)

## EDUCATION



We push to expand global access to BostonSight lens designs. What we did in 2024:

- Expanded the FitAcademy portfolio of educational events, including adding a program to Latin America with an eye on future international expansion
- Implemented new FitSmart dine and learn events with eye care providers around the U.S.
- Created the first BostonSight SCLERAL Global Education Partner Summit to strengthen our robust international consultation team, which supports BostonSight SCLERAL fitters around the world



## BOARD OF DIRECTORS

Pamela Anderson, Esq., Chair  
Sara Yost, MBA, President  
Donna Desmond, MBA, CPA, Director  
Marcus Hughes, Esq., Director  
Howard Purcell, OD, Director  
Michael Raizman, MD, Director  
Ron Remy, MBA, Director  
Clifford Scott, OD, MPH, Director

## CLINICIANS

Daniel C. Brocks, MD  
*Chief Medical Officer*  
Karen G. Carrasquillo, OD, PhD, FAAO, FSLS, FBCLA  
*Senior VP, Clinical and Professional Affairs*  
Alan Kwok, OD, FAAO, FSLS  
*Director of PROSE Network Clinical Relationships*  
Bita Asghari, OD, FAAO, FSLS  
*Associate Director of Clinical Education*  
Chirag Patel, OD, FAAO  
*Associate Director of Innovative Technologies*

## SENIOR STAFF

Sara Yost, MBA, President and CEO  
Cheryl Sadeli, MBA, CPA, Chief Financial Officer  
Laurel Villers, Chief Business Development Officer  
Manoel Carvalho, Director of Lab Operations  
Michele Hart, Director of Marketing and Communications  
Melinda Kimball, Director of Human Resources  
Darlene Riordan, Director of Clinical Operations  
Olga Tomashevskaya, Director of Engineering



## IMPACT

Eyes Treated: 100,000+  
Countries Reached: 40+  
Lives Impacted: Countless

# STRATEGIC PARTNERS

BostonSight is able to achieve our mission around the world through a network of trusted partners, aligned in vision and shared values.

LV Prasad Eye Institute



LVPEI's mission is to provide equitable and quality eye care to all sections of society. Established in 1987, LV Prasad Eye Institute (LVPEI), a World Health Organization Collaborating Centre for Prevention of Blindness, is a comprehensive eye health facility with multiple locations across India.

Moorfields Eye Hospital  
NHS Foundation Trust



The leading provider of eye health services in the UK and a world-class center of excellence for ophthalmic research and education with a reputation, developed over two centuries, for providing the highest quality of ophthalmic care. Moorfields Eye Hospital serves patients throughout the UK.

Conóptica, SL



Conóptica has more than 55 years of experience in the contact lens and optometry industry and provides products, services, and education to eye care professionals to provide effective and tailored visual solutions in Spain, Portugal, and Morocco.

Spectrum  
International



A North American-based company that promotes and exports optical goods and services from certified vendors located in strategic geographical locations. Spectrum represents the best laboratories inside and outside of the United States, in over 65 countries across Latin America and the Middle East.



# DONORS

# LIFETIME GIVING

The Lifetime Giving donor roll recognizes donors who have made significant contributions over the life of their giving.

## \$250,000+

Bausch + Lomb World Headquarters  
Frank Berry  
John W. Henry Family Foundation  
Bruce and Holly Johnstone  
Thomas Anthony Pappas Charitable Foundation  
Michael and Myra McCoy  
Nehemias Foundation  
Renee Rapaporte  
Kate Weingarten

## \$50,000 - \$99,999

Lorne Abony  
Anonymous  
Competitive Technologies  
Michael Moskow  
Oculus, Inc.  
Perry Rosenthal  
Paul Szczygiel

## \$100,000 - \$249,999

Wendy Appel  
Harry and Honore Birkenruth  
Blue Cross Blue Shield of Massachusetts Foundation  
Boston Eye Associates  
The Charles Evans Foundation  
Earmark  
Yuriy Fershter  
Florence Koplow  
John Pevarnik Charitable Trust  
Lauren Marino  
Valya Shapiro  
Enid Starr, Esq.  
Tonna Charitable Trust  
University of Rochester  
Joe and Susan Zienowicz

## \$25,000 - \$49,999

Amelia Peabody Foundation  
Blue Cross Blue Shield of Massachusetts  
Indo-American Eye Care Society  
Resulticks  
Alfoncina Sandoval  
Peter Wilson  
Yawkey Foundation II

# DONORS

# VISIONARY CIRCLE OF HOPE

The Visionary Circle of Hope recognizes donors who have given a gift greater than \$1,000 in the giving year.

## \$25,000 +

Google, Inc.  
Joe and Susan Zienowicz

## \$10,000 - \$24,999

Henry and Diane Bisgaier  
Eugene and Irena Bonte  
Sheryl Erickson  
Paul Ferri  
Julie Rutenberg  
Steven Rutenberg  
Kenneth Sawyer

## \$5,000 - \$9,999

Pamela Anderson  
Bresky Foundation Corporation  
Allan and Anne Greenberg  
Johnson & Johnson  
Joe Martini  
Michael B. Raizman  
Edward Tanzman

## \$1,000 - \$4,999

Brent Archer  
Marci Azbell  
Alyson Berliner  
Harry Branning  
Branning Family Charitable Fund  
Alicia and Glen Bunnell  
Leroy and Jane Crosby  
Michael Daily  
Gerard De Gunzburg  
Michael Dominguez  
Mary Dunbrack  
Eastern Bank Charitable Foundation  
Gary and Susan Fentin  
Renard and Mary Francois  
Karen Grossman

## \$1,000 - \$4,999

Evan Haberman  
Donniel and Adina Hartman  
JP Morgan Chase and Company  
Jay Kelly  
Michael P. and Vicki Link  
Anna K. Mergen  
Latisha Middleton  
Carmen Paradis  
Howard Purcell  
Delia Sattin  
Clifford Scott  
Jonh Sheskey  
George Tonna  
Sara and Jason Yost

# DONORS

2024

## \$500-\$999

Advanced Micro Devices, Inc.  
Thomas and Nancy Artz  
Bank of America  
Glenn Barest  
Gary Bedrosian  
Stephen Blackwell  
Charles and Sarah Shoaf Cabot  
J. Stephen Collins  
Jean and John Conners  
Dennis Corkum  
Alison Farmer  
Vincent Fratello  
Isabelle Garreaud  
Gene Guselli  
Elise Hauenstein  
David Hobson  
Douglas and Edythe Jablonsky  
Dwayne and Deborah Kepner  
Andrea Knight  
Sherri Kraft  
Paul LeVine  
James MacGregor  
Peter and Robin Muise Fund  
Regeneron Pharmaceuticals, Inc.  
Charles Rehn  
Ron Remy  
Craig and Eileen Yarnell

## \$499 and below

Ruth Abelmann  
Rao Addanki  
Gerald and Corinne Adler  
Virginia Alden  
American Endowment Foundation  
Steven Appel  
Norman and Monique Avey  
Bonnie Bader  
Linda Baker  
Mary Bazinet  
Michael Bedrin  
Ed Bennett  
Todd Birkenruth  
Steven Bogatz  
Andrea Bonte Arcuri  
Kathleen Bowen  
Robert Bower  
Joann Bowman  
Helen Bragdon  
Peter G. and Sally Brassard  
Daniel Breen  
Karen Brown  
Robert Brown  
Marcia Burch  
Nancy Busby  
Pamela Cacace-Crepeau  
Ellen Caliendo

## \$499 and below

Abby Caplin  
Lynn Carter  
Steven and Kathleen Case  
Selena Chan  
Ross Connelly  
Wendy Cooper  
Christopher Corrigan  
Susan Costello  
Marc and Lynne Craft  
Stephanie Craig  
Will Craig  
Helene Curley  
Jeanee Decenzo  
Sandra DeFrancisco  
John Delude  
Donna Desmond  
Patricia Donahue Hageman  
Sean and Sarah Dorfman  
Michael Dorsett  
Tammy Downes  
Roberta Drury  
Evelyn Duran  
Julie Echols  
Bernard and Lois Edinberg  
Bethany Ellis  
Annette Estefano  
Debby Fenn

# DONORS

2024

## \$499 and below

Jeanette Flores  
Jamie and Dennis Floyd  
Angela Ford-Rosenthal  
Tarah Foster  
Dr. Catherine Fuchs  
Kim Gavagan  
Judy Geleerd  
Alexandra Gignac  
Karen Ginsberg  
James Gisonde  
Jillian Giuliano  
Give Lively Foundation  
Penelope Gleason  
Rhonna Goodman  
Gary Green  
Lydia and Ron Greenfield  
Peter Greven  
Greg Hamre  
Beverly Hart  
Michele Hart  
HCA Healthcare  
Kenneth Hengeli  
Mari Hirsh  
Judith Hochstadt  
Lois Horowitz  
Linda Howey  
Marcus Hughes

## \$499 and below

Shannon Hughes  
Jeannette Iles  
Deborah S. Jacobs  
David Jacobson  
Frances Jeffries  
Chris and Klavs Jensen  
Dwight Johnson  
Peter Jones  
Jesse Kaminski  
Lyn Kaminski  
Vijay Kannan  
Adolph Karchmer  
Patti Kastner  
Robert and Geraldine Kastner  
Joel Katz  
John and Ellen A. Kelley  
Melinda and Ken Kimball  
Jill Kleeman  
Ellen Knizeski  
Ilene Knopping  
Robert Kopelman  
Ilana Kraus  
Dan and Karen Krugler  
Joanna Kusnierz  
Martine Lalonde  
Chelsea Lane  
Linda Large

## \$499 and below

Theresa Laster  
Camille Leblanc  
Keng Lee  
Klimenty Levin  
Martin Levy  
Viola Lundberg  
John J. and Maria Lynch  
Michele Malgieri  
Sandra Mann  
Raymond and Mary Marble  
Richard and Debra Martinez  
Joseph and Patricia Marzetti  
Matthew and Margarethe Mashikian  
Daniel and Sheila Massarelli  
Mark and Catherine Mathers  
Jack Mayer  
Mark and Sandra Mazur  
Karen McAnern  
Joseph McKeon  
Nancy Miller  
Lewis Mitchard  
McKinley Mitchell  
Scott Nascimento  
Barbara Nelson  
Patricia Nestler  
Bien Nguyen  
Diane Norton

# DONORS

2024

## \$499 and below

Irina Norton  
Maria Noto  
Jayme Nozzi  
Richard and Patricia O'Brien  
Eli Okrant  
Barbara Oravec  
Miriam L. Ornstein  
Kathy Owen  
Palo Alto Networks  
Gina Parkinson  
Linda Patti  
Nancy Paull Nida  
Ken Payne  
Paypal Giving  
Beverly Peiser  
Mary Peled  
Thomas Perosky  
Teri Piatt  
Ellen Pichey  
Tamela Pink  
Stephanie Pisano  
Joan Porco  
Karen Pozzi  
Daniela Prodanovic  
Geraldine Radzanowski  
Anne Redman-Lyon

## \$499 and below

Linda Reichert  
David Rosen  
Leonard Rosenthal  
Barbara Rostosky  
Mark Roux  
James Ruby  
T. Michael Russo  
Robert Ryan  
Jacqueline Sabourin  
Shahzad Saleem  
Seth Salley  
Tim Sanders  
Monserrate Santiago  
Dawn Saunders  
Helga Seiler  
Ruchika Sethi  
Robert Seyler  
Sue Sharer  
Donna Sherman  
Patrick Simard  
Peggy Sisselman  
Amy Smith  
Darlene Smolak  
Rosalind Spigel  
Howard Stoner  
Patricia Szymkiewicz

## \$499 and below

Nancy Tepper  
Alfred Thoman  
Emily Tourtilotte  
Robert VanGrol  
Tatleen Vassell  
Judith Velez  
Laurel and Paul Villers  
Simran Vohra  
Dorothy Waldron  
Michael Watson  
Jonathan Weber  
Jerome Weinstein  
Ma'lis Wendt  
Milan Whalen  
Norman Wilikofsky  
James Willis  
John Wilson  
Manira Wilson-Bassett  
William Wright  
Daniel Wywoda  
Jeremie Xatruch  
Brittany Yelle  
Sandra Yelle  
Janice Yost

## Scleral lenses and their impact on ALS patients



Jacob (center) with his parents.

When 23-year-old Jacob Harper from Winfield, West Virginia, first heard the words “You have ALS,” in March 2022, he and his father sat in shock. Neither had a clear understanding of what the diagnosis meant. His mother, however, turned pale—she knew the weight of those three letters. Amyotrophic lateral sclerosis, or ALS, is a relentless disease. For Jacob, it was not just ALS but an ultra-rare genetic version, linked to the P525L FUS mutation. Doctors told him to expect only one to three years.

Jacob, once an avid outdoorsman who loved hunting, fishing, and working as a machinist and a welder, suddenly faced a future of increasing paralysis and loss. Yet, through determination, faith, and access to an experimental drug called ION363—nicknamed “Jacifusen”—he has lived beyond those initial predictions. Even as the disease advanced, Jacob and his family found new ways to fight for quality of life.

**One of the most unexpected breakthroughs came not from a drug or machine, but from a pair of lenses.**

As ALS progressed, Jacob eventually lost the ability to move his eyes. He could no longer blink, and his eyelids wouldn’t stay open. Severe dry eye followed, leaving his eyes painfully irritated and threatening to take away his ability to watch television, enjoy car rides, or even communicate. At times, his parents resorted to using cosmetic tape to hold his eyelids open. It was an exhausting, imperfect solution that underscored how fragile his remaining independence had become.

Enter scleral lenses. Traditionally used for patients with corneal disease or extreme dry eye, these specialized contact lenses are larger than normal and vault over the eye, creating a reservoir of fluid that bathes the cornea. Jacob’s care team at The Ohio State University had never tried them in someone with ALS before, but they were willing to innovate. Working with Dr. Stephanie Pisano and her team, including a dedicated resident, Dr. Shihij Takoo, Jacob went through multiple fittings to find lenses that worked. They had to account for astigmatism, depth, and comfort, making careful adjustments along the way.

The impact was immediate. With the scleral lenses in place, Jacob’s eyes could stay open and moist, protected from damage and discomfort.

continued on next page


# PATIENT IMPACT

Combined with cosmetic tape, the lenses allowed him to keep his eyes open long enough to enjoy daily life again and, most importantly, stay engaged with the people he loves. His father calls the lenses “a blessing,” explaining, “I don’t know what we would do if it had not been for the scleral lenses. In a world where we had already lost almost everything, and we only had communication left, these lenses made sure we were able to hang on to this piece of dignity.”

Communication is one of the cruellest battlegrounds in ALS. Before his eye paralysis, Jacob was lightning-fast on an eye-gaze computer system, astonishing his speech therapist with his speed. He could email, text, even shop online almost as quickly as before his diagnosis. In fact, it was almost as if his family could have regular conversations with Jacob. As his voice deteriorated, Jacob’s family connected with Bridging Voice, a nonprofit based in New York City, who assists ALS families with communication technology. They were put in touch with ElevenLabs, who uses clips of person’s voice to create an electronic voice. Using videos, they created an AI duplicate that sounded almost identical to Jacob.

When he lost the ability to move his eyes, that option disappeared. Today, he communicates using a neuro-node system connected to his leg muscles. Though slower, it still allows him to share his thoughts and direct his smart home devices. Today, scleral lenses make it possible to keep his eyes open, protected, and moisturized, and interact with his environment, preserving the vital connection between his mind and the outside world.

For the Harper family, the lenses are more than a medical tool. They are a bridge. They have enabled Jacob to remain present in



**“I don’t know what we would do if it had not been for the scleral lenses. In a world where we had already lost almost everything, and we only had communication left, these lenses made sure we were able to hang on to this piece of dignity.”**

everyday moments, whether watching movies with his parents, listening to vinyl records, or taking long drives, where his father straps him into his beloved Mustang and takes him out on the open road.

ALS is a disease defined by relentless loss: the loss of movement, speech, independence, and time. But in Jacob’s case, scleral lenses hit the pause button, allowing him to maintain communication longer. They offer comfort, vision, and dignity in the face of one of life’s harshest challenges. And in doing so, they keep open a window to the world that would have otherwise closed too soon.

Learn more about Jacob’s journey at [www.TeamJacobWV.org](http://www.TeamJacobWV.org)

# FINANCIALS



## INCOME AND EXPENSES (\$ in 000's)

INCOME	12/31/2024	12/31/2023
Network clinic revenue	\$ 4,952	\$ 4,460
Patient services	3,994	3,717
Contributions and grants	452	342
In-kind and other	227	342
Capital grant	98	102
<b>Total Income</b>	<b>\$ 9,722</b>	<b>\$ 8,964</b>
EXPENSES		
Operating and research	7,789	7,104
Education	159	
General and administrative	1,261	1,557
Fundraising	54	66
<b>Total Expenses</b>	<b>\$ 9,264</b>	<b>\$ 8,727</b>
<b>Net Income</b>	<b>\$ 458</b>	<b>\$ 237</b>

The information has been extracted from the IRS form 990 and the financial statements of Boston Foundation for Sight for the years ending December 31, 2023, and 2024 that were audited by the independent certified public accounting firm AAFCPAs.

# BALANCE SHEET (\$IN 000'S)

## ASSETS

### Current assets:

	12/31/2024	12/31/2023
Cash and cash equivalents	\$ 2,607	\$ 2,803
Current portion of restricted cash	26	22
Accounts Receivable - patients	886	957
Accounts Receivable - network clinics	446	479
Accounts Receivable - other	56	30
Inventory	386	423
Prepaid expenses and other	128	118
<b>Total current assets</b>	<b>\$ 4,534</b>	<b>\$ 4,832</b>

### Other assets:

Property and equipment, net	2,909	2,348
Right-of-use assets - Operating	2,244	2,546
Restricted cash, net of current portion	185	185
Deposits	33	33

### Total assets:

\$	9,904	\$	9,943
----	-------	----	-------

## LIABILITIES AND NET ASSETS

### Current liabilities:

Accounts payable and accrued expenses	\$ 829	\$ 816
Current portion of note payable	132	202
Current portion of operating lease liabilities	467	456
Deferred revenue	792	817

### Total current liabilities:

\$	2,220	\$	2,290
----	-------	----	-------

### Operating lease liabilities, net of current portion

1,981	2,271
-------	-------

### Notes Payable, net of current portion

\$	386	\$	523
----	-----	----	-----

### Total liabilities:

<b>4,588</b>	<b>5,084</b>
--------------	--------------

### Net assets:

Without donor restrictions	\$ 5,106	\$ 4,652
With donor restrictions	210	207

### Total net assets:

<b>\$ 5,317</b>	<b>\$ 4,859</b>
-----------------	-----------------

### Total liabilities and net assets:

<b>\$ 9,904</b>	<b>\$ 9,943</b>
-----------------	-----------------



BostonSight  
464 Hillside Avenue, Suite 205  
Needham, MA 02494  
781-726-7337

[www.bostonsight.org](http://www.bostonsight.org)  
[info@bostonsight.org](mailto:info@bostonsight.org)